Should cellular therapy products be tested for human herpesvirus 8? [1]

Transfusion

Volumn 47, Issue 8, 2007, Pages 1550-

  Lefrère, Jean Jacques ^a,b   Guillaume, Nicolas ^b   Laperche, Syria ^a  

^a INSTITUT NATIONAL DE LA TRANSFUSION SANGUINE   (France)

^b AMIENS UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD; BLOOD COMPONENT THERAPY; BLOOD DONOR; BLOOD SAMPLING; BLOOD STORAGE; BLOOD TRANSFUSION; CELL THERAPY; FRANCE; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE DEFICIENCY; INDUSTRIALIZATION; KAPOSI SARCOMA; LABORATORY TEST; LETTER; NONHUMAN; SEROPREVALENCE; UGANDA; UNITED STATES; VIRUS INFECTIVITY; VIRUS TRANSFORMATION;

HERPESVIRUS 8, HUMAN; HUMANS; SARCOMA, KAPOSI; TISSUE THERAPY;

EID: 34547127607     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2007.01350.x     Document Type: Letter

References (6)

1. Hladik W, Dollard SC, Mermin J, et al. Transmission of human herpesvirus 8 by blood transfusion. N Engl J Med 2006 355 : 1331 8.
2. Donegan H, Lee H, Operskalski EA, et al. Transfusion transmission of retroviruses: human T-lymphotropic virus types I and II compared with human immunodeficiency virus type 1. Transfusion 1994 34 : 478 83.
3. Lefrère JJ, Mariotti M, Girot R, Loiseau P, Hervé P. Transfusional risk of HHV-8 infection. Lancet 1997 350 : 217.
4. Tateishi-Yuyama E, Matsubara H, Murohara T, et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet 2002 360 : 427 35.
5. Challine D, Roudot-Thoraval F, Sarah T, et al. Seroprevalence of human herpesvirus 8 antibody in populations at high or low risk of transfusion, graft, or sexual transmission of viruses. Transfusion 2001 41 : 1120 5.
6. Pellett PE, Whright DJ, Engels EA, et al. Multicenter comparison of serologic assays and estimation of human herpesvirus 8 seroprevalence among US blood donors. Transfusion 2003 43 : 1260 8.